Cargando…
Preclinical Cancer Models and Biomarkers for Drug Development: New Technologies and Emerging Tools
BACKGROUND AND PURPOSE: Predicting the efficacy of anticancer therapy is the holy grail of drug development and treatment selection in the clinic. To achieve this goal, scientists require pre-clinical models that can reliably screen anticancer agents with robust clinical correlation. However, there...
Autores principales: | Dhandapani, Muthu, Goldman, Aaron |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5743226/ https://www.ncbi.nlm.nih.gov/pubmed/29285415 http://dx.doi.org/10.4172/2155-9929.1000356 |
Ejemplares similares
-
Cancer Immunotherapy and Personalized Medicine: Emerging Technologies and Biomarker-Based Approaches
por: Maciejko, Laura, et al.
Publicado: (2017) -
Emerging Role of Translational Digital Biomarkers Within Home Cage Monitoring Technologies in Preclinical Drug Discovery and Development
por: Baran, Szczepan W., et al.
Publicado: (2022) -
Ex Vivo Metrics™, a preclinical tool in new drug development
por: Curtis, C Gerald, et al.
Publicado: (2008) -
Editorial: Preclinical models and emerging technologies to study the effects of the tumor microenvironment on cancer heterogeneity and drug resistance
por: Adriani, Giulia, et al.
Publicado: (2023) -
Tumor heterogeneity: preclinical models, emerging technologies, and future applications
por: Proietto, Marco, et al.
Publicado: (2023)